Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma

BACKGROUND. Patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) demonstrate aberrant activation of the phosphotidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway. We examined the efficacy of everolimus, an mTOR inhibitor, in patients with recur...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Head Neck
Autori principali: Geiger, Jessica L., Bauman, Julie E., Gibson, Michael K., Gooding, William E., Varadarajan, Prakash, Kotsakis, Athanasios, Martin, Daniel, Gutkind, Jorge Silvio, Hedberg, Matthew L., Grandis, Jennifer R., Argiris, Athanassios
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2016
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6820341/
https://ncbi.nlm.nih.gov/pubmed/27232378
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hed.24501
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi